IDPC
Ann Fordham

IDPC Secretariat

Ann Fordham

Executive Director

Ann Fordham directs the work of IDPC, leading on the coordination and development of the network. Ann was appointed as Executive Director in 2011. She joined IDPC in 2008 as the first coordinator of the network and in that time has grown the network from 32 to more than 195 organisations. Ann leads on international advocacy efforts on drug policy and human rights, specifically calling for reform of laws and policies that have proven ineffective in reducing the scale of the drug market and have negatively impacted marginalised population groups such as people who use drugs and growers of illicit crops. She represents IDPC at international events and works with policy makers and civil society partners around the world to review and shape drug control policies towards more humane, effective approaches that are based in principles of human rights and public health. Ann was the Chair of the Strategic Advisory Group to the United Nations on drug use and HIV from 2017 to 2023. She is regularly invited to comment on global drug policy issues in the media. She has a Masters Degree in Human Rights from Sussex University where she specialised in human rights and harm reduction.

Contact

Translations

Related Content

5 July 2021
How the United States fuelled a global drug war, and why it must end

How the United States fuelled a global drug war, and why it must end

June 2021 marks 50 years since Richard Nixon declared “drug abuse” the United States’ “public enemy number one.” It is a grim anniversary that resonates not only in the United States but all over the world. The global drug war is an unmitigated human rights disaster, well-documented in painstaking detail. As U.S. domestic drug policy reform gains momentum, it is time the United States makes a concerted effort to de-escalate the failed, harmful, and disastrous global war on drugs. There is reason for hope. After a century as the self-appointed leader of punitive drug enforcement—and billions wasted on the effort—U.S representatives struck a decidedly different tone on the global stage at the UN Commission on Narcotic Drugs. Regina LaBelle, acting director of National Drug Control Policy, gave the United States national statement in April, noting that “we can’t confront today’s challenges with yesterday’s methods; we have to modernize and make sure our approaches are responsive to current trends.” She went on to highlight the Biden-Harris Administration’s Statement of Drug Policy Priorities for Year One and emphasized the administration’s focus on “ensuring racial equity and promoting harm reduction efforts.” The Biden-Harris Administration intends to make a bold shift away from the drug war at home—especially in the face of an unprecedented overdose crisis that has seen more than 70,000 Americans die from a drug overdose in 2019 alone. Their commitment to scaling up harm reduction and evidence-based drug treatment and to ensuring racial equity is crucial and long overdue. It will require a huge and sustained effort to undo decades of harm, especially to communities of color. However, when it comes to U.S. foreign policy, these progressive approaches need to translate into something more than pleasing rhetoric.